NASDAQ$SVRA
Savara Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ending March 31, 2020 and provided a business update.
Savara reported a net loss attributable to common stockholders of $15.4 million, or $(0.27) per share, for the three months ended March 31, 2020. As of March 31, 2020, Savara had cash, cash equivalents, and short-term investments of approximately $105 million.
- Announced expected design for IMPALA 2, the next Phase 3 study of Molgradex in aPAP.
- Obtained global rights to develop and commercialize Apulmiq (inhaled ciprofloxacin) for non-cystic fibrosis bronchiectasis (NCFB).
- Closed enrollment in the Phase 3 AVAIL study of AeroVanc for methicillin-resistant Staphylococcus aureus (MRSA) lung infection due to COVID-19 concerns, with top line results expected in early 2021.
- Closed enrollment in the Phase 2a ENCORE study of Molgradex for nontuberculous mycobacterial (NTM) lung infection due to COVID-19 concerns.
Headline financials
Revenue & EPS history
Savara · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2020
-1.1%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+7.6%
Avg return
30 days after
35%
13 / 37 earnings
Positive
+12.5%
Q3 2018
Best reaction
-20.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.8% | -1.8% | — | |
| Q4 2025 | -0.8% | +3.4% | -3.0% | |
| Q3 2025 | -4.9% | -3.0% | +59.8% | |
| Q2 2025 | +5.5% | +18.2% | +38.0% | |
| Q1 2025 | +9.9% | +23.7% | +13.9% | |
| Q4 2024 | +4.7% | +8.3% | +14.4% | |
| Q3 2024 | -20.1% | -26.8% | -17.7% | |
| Q2 2024 | +4.0% | +9.3% | +8.5% | |
| Q1 2024 | -6.6% | -3.6% | -20.6% | |
| Q4 2023 | -2.2% | -9.2% | -11.8% | |
| Q3 2023 | -6.2% | -0.5% | +12.4% | |
| Q2 2023 | +4.3% | +3.8% | -0.8% | |
| Q1 2023 | +8.5% | +31.7% | +60.8% | |
| Q4 2022 | -3.9% | -15.8% | -7.4% | |
| Q3 2022 | +5.4% | +18.0% | +42.3% | |
| Q2 2022 | +3.0% | -0.6% | -10.8% | |
| Q1 2022 | +3.6% | +20.0% | +28.2% | |
| Q4 2021 | +5.6% | +3.2% | -4.8% | |
| Q3 2021 | -1.7% | -3.4% | -10.3% | |
| Q2 2021 | -3.3% | -4.1% | +17.9% | |
| Q1 2021 | +1.3% | +5.2% | +18.8% | |
| Q4 2020 | -13.6% | -3.8% | +6.0% | |
| Q3 2020 | -3.7% | +3.7% | +32.1% | |
| Q2 2020 | +0.0% | -8.0% | -41.0% | |
| Q1 2020 | -2.5% | +2.1% | +0.8% | |
| Q4 2019 | -2.5% | +0.4% | -10.2% | |
| Q3 2019 | -7.6% | -15.8% | +22.1% | |
| Q2 2019 | -6.5% | -3.7% | -1.6% | |
| Q1 2019 | +2.0% | +0.5% | -7.8% | |
| Q4 2018 | -4.2% | -2.7% | +11.5% | |
| Q3 2018 | +12.5% | +2.9% | -20.3% | |
| Q2 2018 | -2.6% | -7.6% | -2.0% | |
| Q1 2018 | -5.8% | -4.7% | +14.9% | |
| Q4 2017 | -4.5% | -1.0% | -12.4% | |
| Q3 2017 | -4.3% | +4.4% | +49.3% | |
| Q2 2017 | -3.7% | -4.2% | +13.3% | |
| Q1 2017 | -0.5% | -7.4% | -7.9% | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro